1
by Young, Calvin, Severn, Melissa
Published 2020
Canadian Agency for Drugs and Technologies in Health
... prior to initiating biologic therapy will be reviewed. This report expands upon a previously completed...

2
Published 2019
CADTH
... biologic therapy reimbursed for the treatment of moderate to severe plaque psoriasis...

3
by Thompson, Wade, Argáez, Charlene
Published 2019
CADTH
... the clinical and cost-effectiveness of early biologic therapy compared to conventional treatment for Crohn...

4
by Thompson, Wade, Argáez, Charlene
Published 2019
CADTH
... the clinical and cost-effectiveness of early biologic therapy compared to conventional treatment for Crohn...

5
Published 2019
Canadian Agency for Drugs and Technologies in Health
... analysis based on a Markov state-transition model comparing risankizumab with the following biologic...

6
Published 2019
Canadian Agency for Drugs and Technologies in Health
... analysis based on a Markov state-transition model comparing risankizumab with the following biologic...

7
Published 2016
Canadian Agency for Drugs and Technologies in Health
... in patients 2 years and older who are contraindicated to, or have discontinued, any biologic therapy for lack...

8
Published 2016
Canadian Agency for Drugs and Technologies in Health
... in patients 2 years and older who are contraindicated to, or have discontinued, any biologic therapy for lack...

11
Published 2020
Canadian Agency for Drugs and Technologies in Health
... or biologic therapies.2. The comparative efficacy of HP/TAZ compared with other active topical therapies...

12
Published 2020
Canadian Agency for Drugs and Technologies in Health
... model comparing certolizumab pegol with best supportive care (BSC) and the following biologic therapies...

13
Published 2020
Canadian Agency for Drugs and Technologies in Health
... model comparing certolizumab pegol with best supportive care (BSC) and the following biologic therapies...